Expanded Eligibility for COVID-19 Vaccine Booster Shots

After authorization by the Food and Drug Administration, the Centers for Disease Control and Prevention have expanded the recommendations for booster shots to include Moderna and Johnson and Johnson/Janssen (J&J) COVID-19 vaccines as well as heterologous (mix and match) dosing.

Key new CDC booster recommendations:

- **All persons who received a J&J COVID-19 vaccine** should get a single vaccine booster dose at least 2 months after their initial J&J dose. The booster can be J&J or either of the mRNA vaccines.

- **Certain people who received Moderna** for their primary series should receive a single vaccine booster dose at least 6 months after completing the series. The group of eligible persons is the same as for Pfizer and listed below. Note that the Moderna COVID-19 vaccine booster dose is a half dose (50 μg in 0.25 ml).

- Individuals may choose which of the 3 authorized vaccines they would like to receive if they are eligible for a booster dose.

Booster eligibility for individuals who received either Pfizer or Moderna primary COVID-19 vaccine series

- A booster is **recommended** for:
  - People 65 years and older
  - Residents of long-term care facilities
  - People age 50–64 years with an underlying medical condition or are at risk of social inequities

- A booster **may be considered** for:
  - People age 18-49 years with an underlying medical condition
  - People age 18-64 years who are at higher risk of COVID-19 exposure due to their occupational or institutional setting; this includes all essential workers.

These recommendations have been endorsed by the Western States Scientific Safety Review Workgroup.

**Upcoming CDC Booster Dose Resources**

- The CDC is in the process of updating their COVID-19 vaccine clinical considerations and will be releasing an MMWR on the ACIP recommendations.

- The CDC is also hosting a live webinar for healthcare providers: *What Clinicians Need to Know About the Recent Updates to CDC’s Recommendations for COVID-19 Booster Vaccination* Tuesday October 26. 11am-12 pm PST. [Webinar details](#).

*LAC DPH Booster Resources*
For providers: COVID-19 Vaccine Eligibility Summary Table. This table summarizes vaccine eligibility based on the primary series received and the patient age and/or risk factors.

For patients: Booster Dose How to Get Vaccinated webpages (English and Spanish); a COVID-19 Vaccine Eligibility Summary Table in English and Spanish; updated patient vaccine FAQs in English. The www.VaccinateLACounty.com website hosts all COVID-19 vaccine related resource for the public.

See the COVID-19 Vaccine Eligibility Summary Table for Healthcare Providers on the next page.

Visit the LAC DPH COVID-19 Provider Hub and Vaccination Hub
Refresh your browser to view the latest version.

This communication was sent by Claire Jarashow, Director, Vaccine Preventable Disease Control Program, Los Angeles County Department of Public Health

To view this and other communications or to sign-up to receive LAHANs, visit ph.lacounty.gov/ahan.
This table summarizes COVID-19 vaccine eligibility based on the primary series received and the patient age and/or risk factors. The most current version of this table is available online.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Age</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer/Comirnaty &amp; Moderna¹</td>
<td>Primary 2-dose series</td>
<td>Pfizer only</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Additional (3rd) dose¹ recommended for moderate to severely immunocompromised persons at least 28 days after 2nd dose</td>
<td>Pfizer only</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Booster dose² recommended at least 6 months after primary series if the individual:</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>• Resides in a long-term care facility</td>
<td>May receive</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>• Has underlying medical condition or increase risk of social inequities</td>
<td>May receive</td>
<td>May receive</td>
</tr>
<tr>
<td></td>
<td>• Has increased risk of exposure from work or institutional setting</td>
<td></td>
<td>May receive</td>
</tr>
<tr>
<td>Janssen/Johnson &amp; Johnson (J&amp;J)</td>
<td>Primary single-dose series</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Booster dose recommended³ at least 2 months after the 1st dose</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

¹ Moderna has two doses. The full dose (100 μg in 0.5 ml) is authorized for both the primary series and the additional dose for immunocompromised (IC) persons. A half dose (50 μg in 0.25 ml) is authorized for booster doses.

² Booster doses can be the same vaccine as was given in the primary series or it can be a mix-and-match dose. Note: a Moderna booster dose is a half dose (50 μg in 0.25 ml).

³ All persons who received J&J as their primary dose should get a booster dose (including those who are immunocompromised) at least 2 months later. The booster dose can be another J&J vaccine, a Pfizer vaccine, or a Moderna vaccine (half-dose).